Results 61 to 70 of about 10,843 (242)
Iron overload and morbidities in Chinese with non‐transfusion‐dependent thalassaemia
British Journal of Haematology, EarlyView.A cross‐sectional study in Hong Kong included 109 adult and paediatric Chinese patients with non‐transfusion dependent thalassaemia (NTDT). The study found significant chronic health issues in 52% of patients. More severe disease was observed in patients with non‐deletional α‐thalassaemia intermedia, β‐thalassaemia intermedia, advanced age and history ...
Wing‐yan Leung +19 more
wiley +1 more source
Rusty microglia: trainers of innate immunity in Alzheimer's disease [PDF]
, 2018 Alzheimer's disease, the most common form of dementia, is marked by progressive cognitive and functional impairment believed to reflect synaptic and neuronal loss.
Adonis Sfera +6 more
core +2 more sources
Thalassaemia major: the murky story of deferiprone [PDF]
BMJ, 2004 Conducting life saving research properly and quickly is a moral imperative Every year over 200 000 babies are born with thalassaemia major. They have a life expectancy of less than 30 years and are dependent on blood transfusions. Repeated transfusions result in cirrhosis of the liver, cardiomyopathy, endocrinopathies, and death due to haemosiderosis.
openaire +3 more sources
PERBEDAAN KADAR SGOT, SGPT DAN GAMMA GT PADA PASIEN TALASEMIA BETA MAYOR DENGAN KELASI BESI DEFERASIROX DAN DEFERIPRONE [PDF]
, 2016 Background: Iron accumulation in liver in patient with major thalassemia which has already having repeated transfution could cause liver disfuntion. Iron chelation is understood to be needed to reduce the dysfunction of the liver.
Abdussalam, Reza +2 more
core
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin [PDF]
, 2017 Cardiosiderosis is a leading cause of mortality in transfusion-dependent thalassemias. Plasma non-transferrin-bound iron and its redox-active component, labile plasma iron, are key sources of iron loading in cardiosiderosis.
Evans, P +4 more
core +1 more source
Cells, 2020 Deferiprone (DFP), also known as Ferriprox, is an FDA-approved, orally active, iron chelator that is currently used clinically for the treatment of iron-overload, especially in thalassaemia major.
M. Fiorillo +4 more
semanticscholar +1 more source
British Journal of Haematology, 2021 Lifelong iron chelation therapy is critical for patients with transfusion- dependent anaemias, and full adherence to therapy is essential to optimise long- term patient outcomes.
S. Badawy +10 more
semanticscholar +1 more source
Cancer Medicine, Volume 14, Issue 13, July 2025.Iron chelation is a promising yet underexplored strategy for colorectal cancer (CRC) treatment. Iron chelators have a dual role in inhibiting and potentially promoting cancer progression. Iron chelation affects key CRC pathways, including histone methylation, NDRG1 upregulation, Wnt/β‐catenin, and p53 modulation.
Gihani Vidanapathirana +4 more
wiley +1 more source
Combined Therapy with Deferoxamine and Deferiprone
Annals of the New York Academy of Sciences, 2005 Abstract: Therapy with either deferiprone (DFP) or deferoxamine (DFO) is inadequate in achieving negative iron balance in many patients with thalassemia. There are mounting theoretical, experimental, and clinical evidences of increased efficacy when therapy includes both chelating agents.
openaire +4 more sources
Glia, Volume 73, Issue 7, Page 1467-1482, July 2025.Main Points CoPAN affects CoA biosynthesis and leads to iron dyshomeostasis. CoPAN d‐astrocytes show ferroptosis, iron accumulation, senescence, lipid peroxidation, mitochondrial damage and tubulin acetylation loss. Astrocytes recapitulate CoPAN disease.
Anna Cozzi +8 more
wiley +1 more source